Purpose: Programmed cell death 6 (PDCD6) is a calcium sensor participating in T-cell receptor-, Fas-, and glucocorticoid-induced programmed cell death. At the sites of lung tumors, the expression of PDCD6 is higher than that in non-tumor tissues. However, the contribution of variant PDCD6 genotypes to lung cancer is largely unknown. The current study aimed to evaluate the contributions of the PDCD6 rs4957014 and rs3756712 genotypes to the risk of lung cancer. Patients and methods: The contributions of PDCD6 genotypes to lung cancer risk were examined among 358 patients with lung cancer and 716 age-and gender-matched healthy controls by typical polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology.
Introduction
For decades, lung cancer has been the most commonly diagnosed cancer and the leading cause of cancer death all over the world. [1] [2] [3] Although several anticancer therapeutic strategies and technologies are rapidly being developed, the prognosis of lung cancer patients remains very poor, as the overall 5-year survival rates are still less than 15-20%. 4, 5 From an epidemiological viewpoint, the most commonly identified factor in lung development and carcinogenesis is believed to be the individual's longterm history of tobacco consumption, which is also a useful predictor of poor prognosis. [6] [7] [8] In this decade, many case-control studies have reported that specific genotypes are associated with higher lung cancer risk for cigarette smokers than for non-smokers [9] [10] [11] [12] [13] [14] [15] [16] [17] and vice versa. [18] [19] [20] [21] In 2010, Lissowska and colleagues conducted a meta-analysis of 41 global studies and proposed that family lung cancer history, although often not well recorded, is a risk factor for lung cancer. 22 The above studies elucidating the gene-lifestyle interactions in lung cancer risk, with or without attention to smoking status, may provide not only predictive markers for revealing the personalized etiology of lung cancer but also potential targets for personalized therapy and genomic pharmacology. The PDCD6 gene, also known as apoptosis-linked gene 2 (ALG-2), is located on human chromosome 5p15.33 and encodes the 22-kD programmed cell death protein 6. 23, 24 PDCD6 is a Ca 2+ -binding protein capable of interacting with Alix/AIP1 and their orthologs, 25 ASK1, 26 and Sec31A, 27 so as to participate in T-cell receptor-, Fas-, glucocorticoid-, and ER stress-induced apoptosis. 23, 28 In a knockout animal model, PDCD6-deficient mice were developmentally and immunologically normal, indicating that PDCD6 is not essential for physical development or immune function. 29 However, PDCD6-deficient cells were no longer capable of blocking apoptosis induced by TCR, FAS, or dexamethasone signals. 29 The expression levels and genotypes 30 of PDCD6 are associated with cancer risk. In 2003, it was found that PDCD6 was upregulated at tumor sites relative to non-tumor sites among lung cancer patients. 31 With respect to lung cancer genomics, only one paper has investigated the association of PDCD6 genotypes with lung cancer risk. 32 In that study, the T allele of rs3756712 G/T, but not that of rs4957014 G/T, was found to be associated with an increased risk of lung cancer. 32 However, the positive findings reported by them should be validated by other studies, especially those conducted in Asian populations. Thus, in the present study, we aimed to investigate the contribution of PDCD6 genotypes at rs3756712 G/T and rs4957014 G/T single-nucleotide polymorphic sites to the risk of lung cancer and then to examine the joint effect of environmental factors, such as habitual smoking, and PDCD6 genotypes on lung cancer risk in Taiwan.
Materials and methods

Methodology for population data collection
First, we have evaluated the sample size for the study group and the estimated total sample size was 864 (432 in each group) while alpha =5%, power =80%, the proportion of homozygous mutant in the case group =10%, and the difference =5%. 
Methodology for PDCD6 genotyping
Genomic DNA from peripheral blood leucocytes of each subject was extracted with a QIAamp Blood Mini Kit (Blossom, Taipei, Taiwan) and further stored and processed as previously described. 16, 17 Briefly, the polymerase chain reaction (PCR) cycling programs set for PDCD6 genotypes were the following: one cycle at 94°C for 5 min; 35 cycles of 94°C for 30 s, 55°C for 30 s and 72°C for 30 s; and a final extension at 72°C for 10 min. The DNA sequences of the forward and reverse primers for PDCD6 rs4957014 were 5′-TGGTGTTTCATACCATTGACACTTGC-3′ and 5′-CTCAGAACCAAGCAGGTTCCTTCA-3′, respectively. As for PDCD6 rs3756712, the DNA sequences of the forward and reverse primers were 5′-TACAGTGGCAAAG GACCACA-3′ and 5′-CACATTCCAGCACTCACCAC-3′, respectively. Following PCR amplification, the products of PDCD6 rs4957014 and rs3756712 were subject to restriction enzyme digestion with HphI and RsaI (New England BioLabs, Ipswich, MA, USA), respectively. As for PDCD6 rs4957014, the digestible G allele was cut into 113-and 13-base pair contigs, while the indigestible T allele was left intact as a 126-base pair long contig. As for PDCD6 rs3756712, the digestible G allele was cut into 113-and 13-base pair contigs, while the indigestible T allele was left intact as a 126-base pair long contig. Overall, the genotyping process was performed by 2 researchers independently and blindly. Five percent of the samples for PDCD6 were randomly selected for direct sequencing, and the results from PCR-restriction fragment length polymorphism analysis and direct sequencing were 100% concordant with each other.
Statistical analyses
As for sample size, the case and control groups were comprised of 358 and 716 individuals, respectively. To ensure that the controls used were representative of the general population and to exclude the possibility of genotyping errors, the deviation of the genotype frequencies of PDCD6 among the controls from those expected under the assumptions of Hardy-Weinberg equilibrium was assessed using the goodness-of-fit test. Mainly, Pearson's chi-square test was used to compare the distribution of PDCD6 genotypes and alleles between the case and control groups (Tables 2 and 3 ) or between other comparison subgroups (Tables 1 and 4 , and Figures 1 and 2 ). The associations between the PDCD6 genotypes and lung cancer risk were estimated by computing ORs and their corresponding 95% CIs with logistic regression analysis. Any value with p<0.05 was taken to be statistically significant.
Results
The frequency distributions of age, gender, and smoking status for the 358 lung cancer patients and 716 controls are summarized in Table 1 . The average ages of the cases and controls were 64.0 and 64.8 years, respectively, and were not significantly different from each other. The ratio of males to females was approximately 2.33 in both groups (Table 1 ). Since we also applied frequency matching with respect to personal smoking habits when recruiting the healthy controls, there was no difference in the distribution of smokers between the control and case groups (Table 1) . According to the patients' histological data, the percentages by lung cancer subtype were 60.9%, 29.6%, and 9.5% for adenocarcinoma, squamous cell carcinoma, and other histology, respectively (Table 1) .
Both PDCD6 polymorphisms rs4957014 and rs3756712 were successfully genotyped for 358 lung cancer patients and 716 control subjects, and the distributions of PDCD6 rs4957014 and rs3756712 genotypes for all the participants are presented, along with the statistical analysis, in Table 2 . Importantly, the genotypes of PDCD6 rs4957014 were distributed differently between the lung cancer and non-cancer control groups (p=0.0058 for the trend) (Table 2, top). In detail, the PDCD6 rs4957014 heterozygous variant GT was not associated with lung cancer risk (OR =0.90, 95% CI =0.69-1.16, p=0.4086), while the homozygous GG genotype variant was significantly associated with decreased lung cancer risk (OR =0.41, 95% CI =0.23-0.72, p=0.0013) ( Table 2 , top). In the recessive model, the results showed that the GG genotype of PDCD6 rs4957014 was associated with decreased lung cancer risk, compared with the TT + GT genotype ( Table 2 middle ). In the dominant model, the differential distribution of the GT + GG versus wild-type TT genotypes was not so obvious between the lung cancer and control groups (Table 3, bottom). As for PDCD6 rs3756712, the results of codominant, recessive, and dominant models all showed that no genotype of PDCD6 rs3756712 was associated with lung cancer risk ( Table 3) . In order to confirm the findings presented in Tables 2  and 3 , analysis of the allelic frequency distribution for PDCD6 rs4957014 and rs3756712 was performed, and the results are summarized in Table 4 . The data showed that the T allele of PDCD6 rs4957014 was associated with a decreased risk of lung cancer, compared with the G allele. On the other hand, neither the T nor the G allele of PDCD6 rs3756712 was associated with lung cancer risk (Table 4) .
In order to determine the association between the rs4957014 polymorphism of PDCD6 and certain clinical pathologic features, we conducted a stratified analysis of the genotype distribution among patients and healthy controls according to their gender and smoking status, respectively (Figures 1 and 2 ). First, lung cancer patients and controls were stratified according to their gender, and the ORs were analyzed. The results showed that male participants carrying the homologous variant GG genotypes at PDCD6 rs4957014 were at a decreased risk of lung cancer after adjustment for age, smoking, alcohol drinking, and habitual areca chewing (adjusted OR =0.29, 95 % CI =0.14-0.57) (Figure 1, left) . In contrast, there was no significant alteration of lung cancer risk associated with the GT or GG genotypes of PDCD6 rs4957014 in females (Figure 1, right) . Then, lung cancer patients and controls were stratified similarly according to smoking status, and the adjusted ORs were analyzed. The results showed that ever smokers carrying the homologous GG genotypes at PDCD6 rs4957014 were at a decreased risk for lung cancer after adjustment for age, gender, alcohol drinking, and (Figure 2, right) . In contrast, there was no significant alteration of lung cancer risk in non-smokers with the GT or GG genotypes of PDCD6 rs4957014 (Figure 2, left) . In addition, there was no correlation of the studied genotypes of PDCD6 with several clinical indexes, including different histologies, TNM classification, staging, and survival status (data not shown). Figure 1 Contribution of PDCD6 rs4957014 genotype to the lung cancer after stratification by gender. The distributions of TT, GT, and GG genotypes at PDCD6 rs4957014 among males (A) and females (B). Adjusted odds ratios (aORs) were estimated with multivariate logistic regression analysis after adjusted for age, smoking, alcohol drinking, and areca chewing status. Figure 2 Contribution of PDCD6 rs4957014 genotype to the lung cancer after stratification by smoking status. The distributions of TT, GT, and GG genotypes at PDCD6 rs4957014 among non-smokers (A) and smokers (B). Adjusted odds ratios (aORs) were estimated with multivariate logistic regression analysis after adjusted for age, gender, alcohol drinking, and areca chewing status. Discussion PDCD6 has been identified as an apoptosis-related gene, 23 and its encoded protein plays a role as a pro-apoptotic factor in Ca 2+ -dependent T-cell receptor-induced programmed cell death. 33 On the other hand, PDCD6 also exerts an anti-apoptotic action in HeLa cells by facilitating the passage of proliferating cells through the G2/M cell cycle checkpoints. 34 These dual functions of PDCD6 may be explained by the fact that it is a Ca 2+ -binding protein, and after being activated, PDCD6 can interact with various intracellular proteins containing Pro-rich regions, such as Alix (ALG-2-interacting protein X), 35 annexins VII and XI, 36 Sec31A (SEC31 homolog A), 27 and TSG101 (tumor susceptibility gene 101), 35 in a Ca 2+ -dependent manner. cancer, 40 and lung cancer. 32 Interestingly, the investigated cancers in these previous studies were all gender related; nonetheless, the results were controversial and inconclusive. Lung cancer is also one of the smoking-related cancers. Therefore, in the current study, the contribution of PDCD6 (rs4957014 and rs3756712) genotypes, gender, and smoking status to lung cancer risk was evaluated. The highlights of the study included (1) the homozygous GG genotype at PDCD6 rs4957014 was significantly associated with a decreased risk of lung cancer in codominant and recessive models (Table 2) ; (2) The allelic frequency analysis supports the findings outlined in point 1, showing that the G allele of PDCD6 rs4957014 was associated with a decreased lung cancer risk (Table 4) ; and (3) The determinant effect of the PDCD6 genotype on lung cancer risk was more obvious among males ( Figure 1 ) and smokers ( Figure 2 ). The protective effect of the rs4957014 polymorphism of PDCD6 on lung cancer risk found here was supported by the findings of Zhou and He. 32, 40 On the other hand, it has been revealed that the rs3756712 and rs4957014 polymorphisms of PDCD6 significantly increased the risk of endometrial cancer. 38 Further validation in larger and different populations are needed for a more precise and meaningful meta-analysis. Gender is a risk factor for lung cancer. Although the possible mechanism(s) is still largely unknown, it is thought that endocrine-related factors play a critical part in the gender-based difference in lung cancer risk. 41 In the 42 with the ratio being very similar to the gender ratio in this study. In recent years, there has been an increasing trend toward female patients with lung cancer and female smokers in Taiwan, as the prevalence and mortality rates in females with non-smallcell lung cancer adenocarcinoma are very high in Taiwan. Therefore, we were interested in whether the genotype of PDCD6 rs4957014 contributes to the gender difference in lung cancer susceptibility. After stratification by gender, it was found that the genotypes of PDCD6 rs4957014 were differently distributed among males but not among females ( Figure 1 ). One explanation for the trend in female patients with lung cancer is the increase in cigarette consumption among females. The results of epidemiological studies suggest that after controlling for the number of cigarettes smoked, women have a 3-fold higher risk of suffering from lung cancer than men. 41 As mentioned above, cigarette smoking is also a wellknown risk factor for lung cancer. Cigarette smoke may enhance remodeling in the developing human airway smooth muscle through hyperplasia and alteration of the extracellular microenvironment, thus contributing to the development of neonatal and pediatric airway disease. 43 In addition, tobacco smoking can induce DNA lesions, and defects in repair of tobacco carcinogen-induced DNA adducts may contribute to carcinogenesis. 44 Therefore, in the last part, the interaction of the genotype of PDCD6 and cigarette smoking status of the participants was examined. As expected, the results showed that the genotypic distribution of the variant genotypes of PDCD6 rs4957014 was significantly different between lung cancer and control subgroups who were ever smokers (Figure 2, right) . On the contrary, no differential distribution was observed among non-smokers (Figure 2, left) . There was no phenotypic assay reporting that the PDCD6 rs4957014 T allele attenuated its capacity to promote those cells with too much DNA damage or too many DNA adducts caused by smoking as those cells with G allele. Lung cells that survive with unrepaired DNA damage will accumulate genomic instability more easily under chronic exposure to cigarette smoking and thus, increase the risk of lung cancer. Further investigations using cells from patients with different genotypes of PDCD6 rs4957014 should be conducted to explore the joint effects of tobacco smoking and PDCD6 rs4957014 on cancer risk. Likewise, future investigations should be designed based on cells from different genders, drinking status, and other lung cancer risk factors. There are many genome-wide association studies (GWAS) for lung cancer to date. The GWAS methodology is expert in high-throughput and depending on datamining analysis to annotate their work. However, these studies cost a lot and the significant SNPs found by GWAS frequently are not locate in or near a gene and may not easily accessed with further functional analysis and annotation. Therefore, to investigate the hypothesis-driven candidate gene and to examine the association between these SNPs on the gene and the risk of lung cancer were still valuable.
In conclusion, the current study provides solid evidence that the G allele of PDCD6 rs4957014 can serve as a protective biomarker for lung cancer risk in the Taiwanese population, especially among males and smokers.
